Literature DB >> 2149812

Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.

W E Peetermans1, J J Hoogeterp, A M Hazekamp-van Dokkum, P van den Broek, H Mattie.   

Abstract

The efficacies of vancomycin and teicoplanin in an experimental Staphylococcus aureus infection in granulocytopenic mice were related to their activities in vitro and their pharmacokinetic profiles. In vitro teicoplanin had a higher intrinsic activity than vancomycin did; and it also had a more favorable pharmacokinetic profile, resulting in higher peak concentrations in plasma, a longer elimination half-life, and a larger area under the concentration-time curve than those of vancomycin. To predict the antibacterial efficacies of the drugs in vivo on the basis of their activities in vitro and pharmacokinetics, a mathematical model was applied. In the model the in vitro effect was expressed as the difference in growth rate between control cultures and those in the presence of the antibiotic (ER), and the in vivo effect was expressed as the difference between numbers of CFU in control and antibiotic-treated animals (EN). The integral of ER against time, ERt, was calculated by using the concentrations found in vivo. A significant linear relationship was found between EN and ERt for different dosages at the same times (4 h) after drug administration as well as for the same doses at consecutive times, although at the lowest doses of teicoplanin the observed effect was less than the predicted effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149812      PMCID: PMC171956          DOI: 10.1128/AAC.34.10.1869

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Microbiological properties of teicoplanin.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

2.  Cloxacillin and nafcillin: serum binding and its relationship to antibacterial effect in mice.

Authors:  H Mattie; W R Goslings; E L Noach
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

3.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Kinetics of antimicrobial action.

Authors:  H Mattie
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

7.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

10.  Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin.

Authors:  H Lagast; P Dodion; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

View more
  21 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Levels of vancomycin in the cerebral interstitial fluid after severe head injury.

Authors:  Anselmo Caricato; Mariano Pennisi; Aldo Mancino; Gianluca Vigna; Claudio Sandroni; Andrea Arcangeli; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

3.  Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection.

Authors:  T Ferry; I Uçkay; P Vaudaux; P François; J Schrenzel; S Harbarth; F Laurent; L Bernard; F Vandenesch; J Etienne; P Hoffmeyer; D Lew
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-28       Impact factor: 3.267

4.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; F Espersen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.

Authors:  J D Knudsen; K Fuursted; S Raber; F Espersen; N Frimodt-Moller
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 7.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Pharmacokinetics of vancomycin during continuous hemodiafiltration.

Authors:  C Santré; O Leroy; M Simon; H Georges; B Guery; C Beuscart; G Beaucaire
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.

Authors:  H Mattie; B A Sekh; M L van Ogtrop; E van Strijen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.